Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is poised for success as a leader in the biopharmaceutical industry with its innovative technology platform and strong pipeline of potential treatments for metabolic diseases associated with aging. With promising results in clinical trials for BGE-102, coupled with the expertise of their experienced CFO, Bioage Labs has the potential to achieve market success in its target areas of cardiovascular risk, obesity, and diabetic macular edema. However, as with any biopharmaceutical company, there are inherent risks and challenges in research and development that must be considered.

Bears say

Bioage Labs is a biopharmaceutical company that focuses on developing therapeutic products for metabolic and age-related diseases. Despite its impressive technology platform and proprietary human-aging dataset, the company's potential is limited by the uncertainty surrounding the efficacy of its drug candidates, particularly in the context of IL6 biology. Additionally, the company's drug development carries substantial risks, and its financials indicate a potential need for future financing, which could result in dilution for shareholders. Overall, the company's outlook is negative due to the potential for failed clinical trials and uncertain financials.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.